株式会社極東書店トップ商品一覧Cancer Biology and the Nuclear Envelope: Recent Advances May Elucidate Past Paradoxes. Softcover reprint of the original 1st ed. 2014

商品詳細

Cancer Biology and the Nuclear Envelope: Recent Advances May Elucidate Past Paradoxes. Softcover reprint of the original 1st ed. 2014

Cancer Biology and the Nuclear Envelope: Recent Advances May Elucidate Past Paradoxes. Softcover reprint of the original 1st ed. 2014

・ISBN 978-1-4939-5481-0 paper EUR 199.99

¥53,456.- (税込) (※)価格はご注文時の参考価格となります。
納品価格につきましては書籍の入荷時点で確定となります。
版元の原価改定、外国為替の変動等により異なる場合がございますので、予めご了承下さい。

お気に入り
著者・編者Schirmer, Eric C. / de las Heras, Jose I. (eds.),
シリーズ (Advances in Experimental Medicine and Biology)
出版社 (Springer-Verlag New York Inc., US)
出版年月2016
ページ数611 pp.
言語ENG
ニュース番号<A04-83700>

解説

"Nuclear envelope (NE) defects have been linked to cancer biology since the mid-1800s, but it was not until the last few years that we have begun to understand these historical links and to realize that there are myriad ways that the NE impacts on tumorigenesis. The NE is a complex double membrane system that encloses the genome while providing structural support through the intermediate filament lamin polymer and regulating protein/ mRNA trafficking and signaling between the nucleus and cytoplasm via the nuclear pore complexes (NPCs). These functions already provide some mechanisms for NE influences on cancer biology but work in the past few years has elucidated many others. Lamins and many recently identified NE transmembrane proteins (NETs) have been now shown to function in DNA repair, regulation of cell cycle and signaling, apoptosis, cell migration in metastasis and nuclear architecture and morphology. This volume presents a comprehensive overview of the wide range of functions recently identified for NE proteins and their relevance in cancer biology, providing molecular mechanisms and evidence of their value as prognostic and diagnostic markers and suggesting new avenues for the treatment of cancer. Indeed some of these recent links are already yielding promising therapies, such as the current clinical trial of selective inhibitors of the nuclear export factor exportin in certain types of leukemia, melanoma and kidney cancer."